Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-06
2007-03-06
Balasubramanian, Venkataraman (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C544S236000, C544S279000, C544S350000, C546S122000
Reexamination Certificate
active
10928784
ABSTRACT:
Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic or heterocyclic rings.
REFERENCES:
patent: 6207679 (2001-03-01), Cuny et al.
patent: 6258822 (2001-07-01), Geyer et al.
patent: WO-98/47869 (1998-10-01), None
patent: WO 01/00610 (2001-01-01), None
patent: WO 01/30774 (2001-05-01), None
patent: WO 01/58890 (2001-08-01), None
patent: WO 01/68648 (2001-09-01), None
patent: WO 02/24679 (2002-03-01), None
patent: WO 02/28860 (2002-04-01), None
patent: WO 02/30353 (2002-04-01), None
patent: WO 02/30423 (2002-04-01), None
patent: WO 02/41843 (2002-05-01), None
patent: WO 02/44153 (2002-06-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 02/060386 (2002-08-01), None
patent: WO 02/076985 (2003-10-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Graninger et al. Curr. Opin. Rhematol. 13(3) 209-13, 2001.
Shaw et al. Expert Opin. Investig. Drugs 9(7) 1469-1478, 2000.
Day et al. J. Amer. Chem. Soc. 68, 1831-1837, 1946.
Molina et al. Synthesis 2, 225-228, 1993.
Karin, M., 1999, “The Beginning of the End: IκB Kinase (IKK) and NF-κB Activation,”The Journal of Biological Chemistry274(39):27339-27342.
Karin, M., 1999, “How NF-κB is activated: the role of the Iκkinase (IKK) complex,”Oncogene18:6867-6874.
Karin and Delhase, 2000, “The IκKinase (IKK) and NF-κ: key elements in proinflammatory signaling,”Seminars in Immunology12(1):85-98 (Abstract).
May et al., 2000, “Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex,”Science289:1550-1554.
Rossi et al., 2000, “Anti-inflammatory cyctopentenone prostaglandins are direct inhibitors of IκB kinase,”Nature403:103-108.
Woronicz et al., 1997, “IκB Kinase-β: NF-κB Activation and Complex Formation with IκB Kinase-α and NIK,”Science278:866-870.
Browner Michelle F.
Clark David L.
Cushing Timothy D.
Hao Xiaolin
Hawley Ronald C.
Amgen Inc.
Balasubramanian Venkataraman
Jones Day
Syntex (U.S.A.) LLC
LandOfFree
Antiinflammation agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiinflammation agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiinflammation agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3749676